The hormone connection almost no one is talking about, and the data that changes everything for women in midlife Dr. Kristi Sawicki Jun 09, 2026 There’s a conversation happening in functional medicine circles that hasn’t fully made it into mainstream prescribing offices yet. It goes something like this: if you’re a perimenopausal or postmenopausal woman taking a GLP-1 receptor agonist, semaglutide or tirzepatide, and you’re not seeing the results you expected, your estrogen s

GHK-Cu is one of the most studied (and sometimes misunderstood) compounds in longevity research today.

GLP-1 medications entered the mainstream conversation through weight loss. But in academic medicine, GLP-1 signaling has been studied for years in the context of cardiovascular disease, kidney disease, fatty liver disease, and increasingly, neurodegeneration. Now a new question is emerging in longevity circles: What happens if we use very small doses—not for weight loss—but to support metabolic health as we age? This article isn’t about hype. It’s about biology, data, and car

If you’re in perimenopause or menopause, you’ve probably noticed your body changing in ways that feel completely out of your control. You might be eating the same things, training consistently, prioritizing movement, staying hydrated — and still watching body fat creep up, especially around your belly. It’s frustrating, and it’s not your fault . Those changes are driven by biology, not willpower. Here’s the good news: science is giving us new tools that actually address why